Summary: Genmab's partner Roche has filed a CTA with the British MHRA for a
Genmab antibody.
Copenhagen, Denmark; October 2, 2007 - Genmab A/S (OMX: GEN) announced today
that its partner Roche has filed a Clinical Trial Application (CTA) with the
British Medicines and Healthcare products Regulatory Agency (MHRA) for a Genmab
antibody developed under the companies' collaboration. Genmab will receive a
milestone payment from Roche which does not influence Genmab's financial
guidance for 2007.
Under the agreement with Roche, Genmab utilizes its broad antibody expertise and
development capabilities to create human antibodies to a broad range of disease
targets identified by Roche. Genmab receives milestone and royalty payments
based on successful products. In certain circumstances, Genmab may obtain rights
to develop products based on disease targets identified by Roche. If all goals
are reached, the value of the collaboration to Genmab could be USD 100 million,
plus royalties.
“We are pleased that the third antibody created by Genmab under our partnership
with Roche is entering the clinic and to now have eight products in clinical
development,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
“Genmab has now achieved the eleventh milestone under the collaboration.”
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using unique,
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances towards a commercial future, we remain committed to our
primary goal of improving the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
HuMax-ZP3(TM); and UniBody(TM) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Stock Exchange Release no. 46/2007
###
